GFI1 and prostate carcinoma: Finally, analyzing clinical follow yielded Gfi1 methylation implied a worse disease-free survival of prostate cancer patients (log-rank, p = 0.0161) (Figure 6B), suggesting Gfi1 epigenetic silencing as a promising biomarker for prostate cancer progression.